<DOC>
	<DOC>NCT01577121</DOC>
	<brief_summary>To demonstrate if indomethacin associated to conventional treatment for preterm labor is useful to delay delivery and to improve neonatal morbimortality in women with preterm labor with high risk of intraamniotic inflammation</brief_summary>
	<brief_title>Evaluation of the Use of Indomethacin as Co-treatment in Women With Preterm Labor and High Risk of Intraamniotic Inflammation</brief_title>
	<detailed_description>Randomised patients would be assigned to receive indomethacin either placebo oral use(50 mg every 6 hours during 5 days) to evaluate the efficacy of indomethacin as complementary treatment to increase the gestational age at delivery in women admitted with preterm labor and intact membranes with high risk of intraamniotic inflammation, defined as a gestational age at admission less than 28.0 weeks or those women from 28-32.0 weeks with a sonographic cervical length less than 15 mm</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Obstetric Labor, Premature</mesh_term>
	<mesh_term>Indomethacin</mesh_term>
	<criteria>pregnant women with preterm labor admitted to hospital and treated with tocolysis pregnant women less than 28.0 and those women from 28.0 to 32.0 with a sonographic cervical length &lt; 15 mm single pregnancy normal amniotic fluid normal arterial ductus Age below 18 years previous use of indomethacin in the index pregnancy chorioamnionitis, preterm prelabour rupture of membranes or those fetal or maternal pathologies which could be responsible of an iatrogenic preterm delivery. oligohydramnios allergy to NSAID previous history of gastrointestinal bleeding use of NSAID contraindicated not adherence to the study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Preterm labor</keyword>
</DOC>